戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 -cause mortality; P=0.001 for cardiovascular end point).
2 l phase (-126.3 minutes at 1-year open-label end point).
3 sociated acute kidney injury was a secondary end point.
4                       Safety was a secondary end point.
5 t and overall survival (OS) as the secondary end point.
6 t, compared with 51% with the CTC conversion end point.
7 , and 30 min postadministration was the main end point.
8 pT0/is ypN0 definition was used as a primary end point.
9 ty score-matched populations was the primary end point.
10 ereas AAA diameters were quantified at study end point.
11 survival and overall survival were secondary end points.
12 -one primary end points (81%) were surrogate end points.
13 ack hub registry and a selection of new REST end points.
14 lished data and across primary and secondary end points.
15 ial-level milestone ratios with conventional end points.
16 er PTA for both the safety and effectiveness end points.
17 ost primary outcomes were based on surrogate end points.
18 to decline compared with control eyes at all end points.
19 idered as alternatives to specific assays or end points.
20 uire confirmation using traditional efficacy end points.
21  or physiological magnetic resonance imaging end points.
22 d progression-free survival were the primary end points.
23 a that capture financial and quality-of-life end points.
24 t significantly improve any of the secondary end points.
25  evident across multiple clinically relevant end points.
26 Efficacy and pharmacodynamics were secondary end points.
27  of individual components of these composite end points.
28 er in vessels with vessel-oriented composite end point (0.88+/-0.06 versus 0.90+/-0.06, respectively;
29              Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24
30 ignificantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%
31 ting data across human health and ecological end points, (3) facilitating cross-species dose-response
32 mized to ferric citrate achieved the primary end point (61 [52.1%] versus 22 [19.1%] with placebo; P<
33               One hundred twenty-one primary end points (81%) were surrogate end points.
34 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.8
35 gest a clinically relevant effect on cardiac end points after early conversion from CNI to a CNI-free
36                                Falsification end point analyses of vascular complications, bleeding,
37 s compared between the 2 arms as the primary end point and overall survival (OS) as the secondary end
38 ing strategy was used for the second primary end point and the secondary end points in the final anal
39 s uncoupled as nucleosome sliding reaches an end point and this is controlled by the Ino80CTD.
40 nic populations and for quantifying anatomic end points and response to therapy in AMD clinical trial
41 vascular coupling responses were measured at end point ( approximately 7 months of age), together wit
42                                  The primary end point at 12 months was similar between groups.
43  Academic Research Consortium-2 early safety end point at 30 days was 7.4% with both devices with no
44  of 661 with motor diagnosis as the survival end point but only 177 with a total motor score PFS.
45 eability using integrated electrodes and the end-point characterization of the endothelium through im
46  study was a randomized, open-label, blinded end-point clinical trial conducted in 8 comprehensive st
47 le patients could be evaluated with the CTC0 end point, compared with 51% with the CTC conversion end
48                                    Composite end point components were ranked according to importance
49 Evolocumab significantly reduced the primary end point consistently in patients with PAD (hazard rati
50 ectionally consistent effects on the primary end point (death, myocardial infarction, ischemia-driven
51 tors, there was no difference in the primary end point, death or unplanned reintervention to treat cy
52 f complete remission and the composite renal end point did not differ significantly between groups.
53  DCB to facilitate the development of future end point-driven randomized studies.
54 ological measures) with the probabilities of end points (e.g., death or system failure).
55                     We conducted a secondary end point evaluation of HRAE (survival free of any nonsu
56 p, open-label treatment trial with a blinded end-point evaluation to compare GA with CS for treatment
57 months beyond catheter ablation by a blinded end-point evaluation.
58                                    A primary end-point event occurred in 68 of 1012 patients (6.7%) i
59 n of a target nucleic acid by digitizing the end-point fluorescence of the parallel micro-PCR reactio
60                          As a standard study end point for first-line FL therapy, progression-free su
61 lore milestone rate, a proposed intermediate end point for immunotherapy trials.
62 n of genetic susceptibility to NFT, a common end point for multiple different pathologic processes.
63 tment with chemoimmunotherapy as a surrogate end point for progression-free survival (PFS) in chronic
64 ld be considered as one of the most relevant end points for transplant-eligible and elderly fit patie
65                                   The 5-year end point-free renal survival was 64.5% (95% CI, 57.4-71
66       Conclusion The CTC0 and CTC conversion end points had the highest discriminatory power for over
67                   Thus, the bound states-one end point-have been thoroughly characterized, but the un
68 and LAS independently indicated the combined end point (hazard ratio = 2.8 and 1.9, respectively; P <
69 dialysis independence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12
70 port the integration of MRD assessment as an end point in clinical trials of MM.
71 or interpret trial results or as a secondary end point in exploratory studies.
72 he use of gamma-band ASSR as a translational end point in pro-cognitive drug discovery and early-phas
73 cy model supports use of PB-MRD as a primary end point in randomized clinical trials of chemoimmunoth
74             The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76
75 , fewer toxic effects, and improved survival end points in an animal tumor model, the authors conclud
76 , using a risk-based approach to ecotoxicity end points in conjunction with mass removal.
77 and prostate-specific antigen (PSA) response end points in five prospective randomized phase III tria
78 ht to determine whether the use of composite end points in major cardiovascular trials has changed ov
79 e second primary end point and the secondary end points in the final analysis.
80  more likely to achieve the primary efficacy end point: in trial A, 188 of 254 (74.0%) vs 21 of 254 (
81                                    Secondary end points included a composite of mortality, clinical i
82                                    Secondary end points included anatomic patency, adverse event rate
83                                    Secondary end points included cardiac magnetic resonance-determine
84                                    Secondary end points included change in body weight and cardiometa
85                                    Coprimary end points included change in brachial artery flow-media
86                                  Exploratory end points included change in high-sensitivity C-reactiv
87                                    Secondary end points included changes in LV volumes, infarct size,
88                                    Secondary end points included clinical outcomes (major adverse car
89                                    Secondary end points included disease-free survival and the cumula
90                                    Secondary end points included intraoperative and postoperative com
91 d point was in-hospital mortality; secondary end points included new-onset organ failure.
92                                    Secondary end points included number of days of use of other illic
93                                    Secondary end points included other visual analog scale (eg, high
94     The primary end point was PFS; secondary end points included overall survival (OS), objective res
95                                    Secondary end points included overall survival and subgroup analys
96                                    Secondary end points included overall survival, distant metastasis
97                                    Secondary end points included overall survival, local and regional
98                                    Secondary end points included overall survival, objective response
99                                    Secondary end points included overall survival, safety, and biomar
100                                    Secondary end points included relapse-free survival (RFS) and TRM.
101                                    Secondary end points included repeat revascularization and a compo
102                                              End points included safety (primary), objective response
103                                    Secondary end points included safety, assessed as the rate and gra
104                                The secondary end points included short-term weight loss, serum obesit
105                                        Other end points included target lesion revascularization, thr
106                                    Secondary end points included the incidences of nonvertebral and h
107                                    Secondary end points included the proportion of patients with at l
108                                    Secondary end points included the rate of nocturnal symptomatic hy
109                            The key secondary end points included time to first SRE and skeletal morbi
110                                    Secondary end points included time to second progression or death,
111 ectively defined to identify relevant safety end points, including arterial thromboembolic events, MI
112 examined the association of age with related end points, including overall biopsy-determined progress
113                             Use of composite end points increased significantly over time from 18.8%
114                               Among examined end points, inverse associations were observed for death
115  C h(-1) and taken to the same physiological end point (just prior to heat coma).
116 antly better outcome regarding the composite end point (malignant ventricular arrhythmias, end-stage
117                                  Use of this end point may expedite therapeutic development with the
118                                    Secondary end points, measured as continuous variables, included p
119 y based on chemical extraction, representing end point measurements.
120 luated over macro-ecological time scales and end-point measurements.
121                              Among secondary end points, nasal symptoms were worse in the intradermal
122                          Further, epigenetic end points need to be correlated with observable detrime
123 utide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stro
124                                  The primary end point occurred in 110 of 2511 patients (4.4%) in the
125                                  The primary end point occurred in 87 patients (52%) in the levosimen
126 antly though modestly improved the composite end point of all-cause mortality or HF hospitalization w
127 ly lower occurrence of the primary composite end point of all-cause mortality, restenosis, or definit
128                                  The primary end point of arrhythmic events was defined as appropriat
129 docardial mitral isthmus line (MIL) with the end point of bidirectional block may be challenging and
130 0 to 0.99) and a lower risk of the composite end point of brain damage, nursing home admission, or de
131 e report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown t
132                                  The primary end point of CKD progression was a composite of 50% eGFR
133 sociated with increased risk of the combined end point of death or transplantation.
134 an follow-up of 3.9+/-2.4 years, the primary end point of death, transplant, or admission for heart f
135 ring surgery at Week 25 based on a composite end point of endoscopic nasal polyp score and nasal poly
136                    The rate of the composite end point of extensive chronic GVHD and relapse-free sur
137              For the principal effectiveness end point of ischemic stroke/systemic embolism, no signi
138 e classified as having had CED or a combined end point of neurological-etiology death or survival.
139 al imprinting alterations, implying a common end point of pathogenesis.
140 in a significant difference in the composite end point of prolonged catecholamine infusion, use of le
141 area under the curve, 0.78) and the combined end point of RVAD or death within 14 days (area under th
142 ctors for RVAD implantation and the combined end point of RVAD or death within 14 days of LVAD were a
143                    At 12 months, the primary end point of target lesion failure (composite of cardiac
144 h zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had
145                                  The primary end point of the study was percentage diameter stenosis
146                                  The primary end point of the trial was cardiovascular death, myocard
147                                  The primary end point of ventricular arrhythmias during exercise was
148 and obligate nonbiting populations represent end points of divergence between fully interfertile sout
149 t between-group differences in the secondary end points of scores for working memory (change in raw s
150 consensus exists on the critical targets and end points of the procedure.
151    Structurally, this represents the current end-point of an extensive medicinal chemistry endeavor t
152                        None of the secondary end point or day-30 all-cause mortality or heart failure
153 reatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality.
154 y have limited ability to address individual end points or safety concerns.
155 d acetylcysteine with respect to the primary end point (P=0.33).
156 ation between stent fracture and the primary end point (P=0.86) or with restenosis (P=0.53).
157 2.5 mug, add-on therapy improved the primary end point, peak FEV1 within 3 hours after dosing (5 mug,
158     Digital polymerase chain reaction (dPCR) end point platforms directly estimate the number of DNA
159                                  The primary end point, progression-free survival (PFS), was evaluate
160 owed a reduced branching rate (-14%), a high end-point rate (+25%) and an increased lacunarity (+139%
161                                All secondary end points reached statistical significance in the ferri
162 ures remained collectively stable (composite end point relative to baseline values) in >/=85% of pati
163                  The analysis of the primary end point showed noninferiority of the study device rela
164                                        Major end points subsequent to first MI were assessed using la
165 ising proof-of-concept trials with surrogate end points such as infarct size to larger clinical outco
166  a particular new drug using an intermediate end point, such as MRD, would require confirmation using
167 and lag between these changes and acceptable end points, such as ESRD, has limited its utility.
168 research that evaluates not only traditional end points, such as mortality and readmission, but also
169 edictive biomarkers and novel clinical trial end points, such as volumetric measurement, magnetic res
170 inical response criteria for the two primary end points than did those who received placebo.
171 up of 15 months and a hierarchical composite end point that evaluated the initial 48-hour clinical co
172 als are more likely to use primary composite end points that contain a larger number of components.
173                        For the key secondary end point, the HRs were 0.73 (0.59-0.91; P=0.0040) for t
174         Conclusion The study met its primary end point; the objective response rate was significantly
175 arlier access to newer therapies, an earlier end point to expedite clinical trials is needed.
176 ons, such as duration of therapy and optimal end points to evaluate efficacy of drugs in clinical pra
177 prospective, randomized, open-label, blinded end point trial, consenting patients with type 2 diabete
178  -28 to 99; P = .27]), and the key secondary end point, trough FEV1 (5 mug, 87 mL [95% CI, 19-154; P
179  variety of biological systems affect apical end points used in regulatory risk assessments, and with
180 timing of antifungal administration, and the end points used to assess antifungal activity affect the
181 nths, the estimated incidence of the primary end point was 12.6% in the TAVR group and 14.0% in the s
182                                  The primary end point was 2-year progression-free survival.
183                                  The primary end point was a change in peak oxygen uptake (Vo2) from
184                                  The primary end point was a change in the villous height:crypt depth
185                         The primary efficacy end point was a composite of adjudicated cardiovascular
186                                  The primary end point was a composite of death, the need for dialysi
187                                  The primary end point was a glycated hemoglobin level lower than 7.0
188                                  The primary end point was achieved in 164 patients in the study grou
189                                  The primary end point was adjudicated AF lasting 6 or more minutes a
190                         The primary efficacy end point was airflow decline-free survival at 2 years a
191                                      Primary end point was all-cause mortality or disabling stroke wi
192                                The secondary end point was association between discordant IOP measure
193                                  The primary end point was centrally assessed PFS.
194                         The primary efficacy end point was cGVHD response based on 2005 National Inst
195                         The primary efficacy end point was change in serum phosphate concentration fr
196                                  The primary end point was complete remission (CR) or CR with partial
197                            The primary study end point was coronary collateral flow index as obtained
198                                  The primary end point was daily combined symptom-medication scores d
199                                  The primary end point was death, myocardial infarction, or unstable
200                            A primary cardiac end point was defined as symptomatic congestive heart fa
201                                  The primary end point was development of HGD or EAC.
202                                  The primary end point was dual: a composite of all-cause mortality a
203                                  The primary end point was dysplasia missed by the first colonoscopy
204                                  The primary end point was endothelial integrity and muscular damage
205                                  The primary end point was event-free survival (with an event defined
206                                  The primary end point was first incident stroke.
207                         The primary efficacy end point was freedom from AF between 90 and 365 days af
208                           The primary safety end point was freedom from device- and procedure-related
209                                  The primary end point was freedom from repeat coronary revasculariza
210                                      Primary end point was hemodialysis independence at 3 months; sec
211                                      Primary end point was in-hospital mortality; secondary end point
212                                  The primary end point was incident diverticulitis.
213                               The prognostic end point was long-term mortality.
214                                  The primary end point was major adverse cardiac events defined as al
215                           The primary safety end point was major adverse cardiac, cerebrovascular, an
216                           The primary safety end point was major bleeding.
217                                  The primary end point was maximal decrease in FEV1 during 10 days af
218                         The primary efficacy end point was met by 71.2% versus 69.3%, in the LB and R
219                    The primary effectiveness end point was met, and superiority of DCB over PTA was a
220                           The primary safety end point was met, and superiority was demonstrated; fre
221                                  The primary end point was new HF assessed over acute (0-6 months) an
222                         The primary efficacy end point was noninferiority of etelcalcetide at achievi
223                         The 30-day composite end point was not significantly different between suctio
224                                  The primary end point was objective response rate evaluated by inves
225                                  The primary end point was OS 18 months post-random assignment based
226                                  The primary end point was OS.
227                                  The primary end point was overall response rate (ORR).
228                                  The primary end point was overall survival (OS) of patients who were
229                                      Primary end point was overall survival (OS), and secondary end p
230                                      Primary end point was overall survival (OS).
231                                  The primary end point was overall survival.
232                                  The primary end point was patient participation in CRC screening 1 y
233                                  The primary end point was PFS; secondary end points included overall
234                    The primary effectiveness end point was primary patency at 12 months.
235                                  The primary end point was progression-free survival (PFS).
236                                  The primary end point was progression-free survival by response asse
237                                  The primary end point was reached by 25 ablation patients and 26 ICD
238                                  The primary end point was relapse-free survival (RFS).
239                                  The primary end point was remission at 8 weeks.
240                                  The primary end point was RT-PCR-confirmed, protocol defined, influe
241                                The secondary end point was safety, assessed by the number and intensi
242                                  The primary end point was seroconversion or a >/=4-fold rise in anti
243                                      Primary end point was short-term (in-hospital or 30 days) mortal
244                                The composite end point was significantly lower in the RA group (8.8%;
245                                  The primary end point was spontaneous preterm birth at less than 34
246                                  The primary end point was sustained virologic response at 12 weeks a
247                                  The primary end point was target-vessel failure (a composite of card
248                                  The primary end point was the annualized rate of asthma exacerbation
249                                  The primary end point was the change from baseline in LDL cholestero
250                                  The primary end point was the change from baseline to months 4 throu
251                                  The primary end point was the change in convulsive-seizure frequency
252                                  The primary end point was the change in Hb at day 7.
253                                  The primary end point was the change in NT-proBNP levels from baseli
254                                  The primary end point was the change in peak VO2 from baseline to 24
255                         The primary efficacy end point was the composite of all-cause mortality, myoc
256                                  The primary end point was the composite of aneurysm rupture or repai
257                   The key secondary efficacy end point was the composite of cardiovascular death, myo
258                                  The primary end point was the composite of incident heart failure, a
259                                  The primary end point was the detection of bone lesions at diagnosis
260                                  The primary end point was the development of asthma until age 12 yea
261                         The primary efficacy end point was the disappearance of the reticular veins w
262                                  The primary end point was the efficacy of three doses of vaccine as
263                                  The primary end point was the identification of the maximum tolerate
264                                  The primary end point was the incidence of somatic mutations of the
265                                  The primary end point was the number of patients no longer requiring
266                                  The primary end point was the percentage of patients with disability
267                                  The primary end point was the proportion of patients with 1 or more
268                                  The primary end point was the rate of overall survival.
269                                          The end point was the risk difference in the onset of new al
270                                Primary study end point was the time to first recurrence of ventricula
271                                  The primary end point was treatment efficacy measured as the respons
272 dy fat redistribution, and the main specific end point was visceral adipose tissue (VAT).
273                                  The primary end-point was the 2007 international working group compl
274 trategy index of executive function (primary end point) was -0.21+/-2.62 in the evolocumab group and
275 hs of single implanted stents (n=71, primary end point) was 95.2+/-5.2% and of combined single and ov
276                                    Secondary end points were a 50% or greater reduction in mean migra
277                              The two primary end points were a four-component composite of death thro
278                                     Clinical end points were AD dementia and any type of dementia aft
279                           Secondary ischemic end points were also evaluated.
280                       Key secondary efficacy end points were change from baseline to days 42 and 14 i
281                                    Secondary end points were change in 6-minute walk distance, plasma
282                          Three time-to-event end points were considered: disease-free-survival, breas
283                                      Primary end points were feasibility and safety.
284                              Secondary study end points were fractional flow reserve during vessel pa
285                                    Secondary end points were frequency of infections, treatment-relat
286                               Main secondary end points were overall survival and bronchiolitis oblit
287                                    Secondary end points were patient-reported toxicity, overall survi
288 int was overall survival (OS), and secondary end points were progression-free survival (PFS), respons
289                                              End points were safety, response, pharmacokinetics, and
290                            The key secondary end points were T-cell persistence and their antigliobla
291                              The two primary end points were the accrued weeks of remission over a 52
292                                    Secondary end points were the change in the mean number of mucosal
293                                  The primary end points were the cumulative incidence of new vertebra
294                                The coprimary end points were the mean score for disability on the uti
295                                    Secondary end points were the number of telephone calls and emails
296                                  The primary end points were the percentage of patients who had at le
297                                      Primary end points were the proportion of patients who had an Am
298                     The two primary efficacy end points were the proportion of women who had a clinic
299                                  The primary end points were treatment safety and tumor response.
300 time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top